Strategies for entering the European orphan drugs market
Choosing your option
Launching a new orphan drug in Europe for the first time can be a daunting prospect for US biotech and pharma companies. The 27 nations which make up the EU bring 24 different languages, and almost as many diverse cultures, healthcare systems, regulations, and reimbursement approaches.
This can all be incredibly complicated to navigate, but the potential rewards are considerable. The good news is that there are different approaches to choose from which can make entering the market simpler and reduce the burden of risk faced by the launching firm.
Download this exclusive guide to learn how more about ways to navigate the complex European landscape, including takeaways on:
- The different approaches you can take;
- The pros and cons of each approach;
- What to look for in a potential European partner.